These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 27318122)

  • 1. Inside HDACs with more selective HDAC inhibitors.
    Roche J; Bertrand P
    Eur J Med Chem; 2016 Oct; 121():451-483. PubMed ID: 27318122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inside HDAC with HDAC inhibitors.
    Bertrand P
    Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
    Christianson DW
    Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylases: structural determinants of inhibitor selectivity.
    Micelli C; Rastelli G
    Drug Discov Today; 2015 Jun; 20(6):718-35. PubMed ID: 25687212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How the flexibility of human histone deacetylases influences ligand binding: an overview.
    Deschamps N; Simões-Pires CA; Carrupt PA; Nurisso A
    Drug Discov Today; 2015 Jun; 20(6):736-42. PubMed ID: 25597521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
    Ganai SA
    Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
    Luo Y; Li H
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach.
    Hsu KC; Liu CY; Lin TE; Hsieh JH; Sung TY; Tseng HJ; Yang JM; Huang WJ
    Sci Rep; 2017 Jun; 7(1):3228. PubMed ID: 28607401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies.
    Brindisi M; Cavella C; Brogi S; Nebbioso A; Senger J; Maramai S; Ciotta A; Iside C; Butini S; Lamponi S; Novellino E; Altucci L; Jung M; Campiani G; Gemma S
    Future Med Chem; 2016 Sep; 8(13):1573-87. PubMed ID: 27556815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
    De Vreese R; D'hooghe M
    Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylases as targets for multiple diseases.
    Sangshetti JN; Sakle NS; Dehghan MH; Shinde DB
    Mini Rev Med Chem; 2013 Jun; 13(7):1005-26. PubMed ID: 22876951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
    Qin HT; Li HQ; Liu F
    Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
    Cho M; Choi E; Yang JS; Lee C; Seo JJ; Kim BS; Oh SJ; Kim HM; Lee K; Park SK; Kwon HJ; Han G
    ChemMedChem; 2013 Feb; 8(2):272-9. PubMed ID: 23292995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical and structural biology of protein lysine deacetylases.
    Yoshida M; Kudo N; Kosono S; Ito A
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(5):297-321. PubMed ID: 28496053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016).
    Zhan P; Wang X; Liu X; Suzuki T
    Recent Pat Anticancer Drug Discov; 2017; 12(1):16-34. PubMed ID: 27804867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.
    Song D; Lee C; Kook YJ; Oh SJ; Kang JS; Kim HJ; Han G
    Eur J Med Chem; 2017 Jan; 126():997-1010. PubMed ID: 28011426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors.
    Krishna S; Kumar V; Siddiqi MI
    Curr Top Med Chem; 2016; 16(9):934-47. PubMed ID: 26303428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity.
    Godoy LD; Lucas JE; Bender AJ; Romanick SS; Ferguson BS
    Mol Nutr Food Res; 2017 Apr; 61(4):. PubMed ID: 27981795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11.
    Madsen AS; Kristensen HM; Lanz G; Olsen CA
    ChemMedChem; 2014 Mar; 9(3):614-26. PubMed ID: 24375963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.